Author

M. C. Chao

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:whole-genome sequencing· 2 Organism:bacteria (other)· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

S. M. Fortune· 3 shared E. J. Rubin· 2 shared J. Zhu· 2 shared N. C. Howard· 2 shared N. D. Hicks· 2 shared Q. Liu· 2 shared S. Stanley· 2 shared X. Wang· 2 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

S. M. Fortune

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Vaginal lactobacilli produce anti-inflammatory beta-carboline compounds.

C. A. Webber, V. J. Glick, M. Martin, C. Kim, M. Ahmad, L. E. Simmons, S. Bang, M. C. Chao, N. C. Howard, S. M. Fortune, L. K. Beura, S. Y. Lee, J. Clardy, K. H. Kim, S. Gopinath

This study identifies beta-carboline compounds produced by vaginal lactobacilli that reduce inflammation by suppressing immune signaling pathways and demonstrate therapeutic potential in a mouse model.

bioRxiv · Feb 19, 2024 · PreprintMicrobiology

High-throughput phenogenotyping of Mycobacteria tuberculosis clinical strains reveals bacterial determinants of treatment outcomes

S. Stanley, C. N. Spaulding, Q. Liu, M. R. Chase, D. T. M. Ha, P. V. K. Thai, N. H. Lan, D. D. A. Thu, N. L. Quang, J. Brown, N. D. Hicks, X. Wang, M. Marin, N. C. Howard, A. J. Vickers, , S. M. Fortune

This study uses high-throughput phenogenotyping to link Mtb genetic variants to clinical outcomes, identifying bacterial traits associated with treatment failure and transmission.

bioRxiv · Apr 9, 2023 · PreprintMicrobiology

Chemically-induced targeted protein degradation in mycobacteria uncovers antibacterial effects and potentiates antibiotic efficacy

H. I. Won, J. Zhu, O. Kandror, T. Akopian, I. D. Wolf, M. C. Chao, M. Waldor, E. J. Rubin

This study uses a genetic system to screen essential proteins in Mycobacterium smegmatis, identifying labile targets for PROTACs and showing their potential to enhance antibiotic efficacy.

bioRxiv · Feb 14, 2023Microbiology

Tuberculosis treatment failure associated with evolution of antibiotic resilience

Q. Liu, J. Zhu, C. L. Dulberger, S. Stanley, S. Wilson, E. S. Chung, X. Wang, P. Culviner, Y. J. Liu, N. D. Hicks, G. H. Babunovic, S. R. Giffen, B. B. Aldridge, E. C. Garner, E. J. Rubin, , S. M. Fortune

The paper identifies resR as a target of positive selection in Mtb clinical isolates, linking its mutations to antibiotic resilience and treatment failure.

bioRxiv · Mar 29, 2022Microbiology